In Vitro/In Vivo Evaluation of Radiolabeled [99mTc(CO)3]+-Hydroxyurea and Fluorescein Isothiocyanate-Hydroxyurea

Basit Öğe Kaydı
dc.contributor.authorYilmaz B.
dc.contributor.authorTeksoz S.
dc.contributor.authorKilcar A.Y.
dc.contributor.authorUcar E.
dc.contributor.authorIchedef C.
dc.contributor.authorMedine E.I.
dc.contributor.authorAri K.
dc.date.accessioned2019-10-27T08:20:41Z
dc.date.available2019-10-27T08:20:41Z
dc.date.issued2016
dc.departmentEge Üniversitesien_US
dc.description.abstractThe aim of current study is to examine hydroxyurea (HU), which is an antineoplastic drug used for the treatment of leukemia, sickle-cell disease, HIV, psoriasis, thrombocythemia, and various neoplastic diseases in two aspects. The active ingredient hydroxyurea was obtained by purification of the capsule form drug, commercially named as HYDREA. Then, [99mTc(CO)3]+core radiolabeling with HU was performed as first aspect. Quality control studies of 99mTc(CO)3-HU complex were performed by thin-layer radiochromatography and high-performance liquid radiochromatography methods. The results demonstrated that the radiolabeling yield was quite high (98.43% ± 2.29%). Also, 99mTc(CO)3-HU complex has good stability during the 24-hour period. Biological behavior of 99mTc(CO)3-HU complex is evaluated by biodistribution studies on Wistar Albino rats. Fluorescein isothiocyanate (FITC) labeling of HU was performed as second aspect. Fluorometric evaluation of binding efficacy and fluorescence imaging studies on MCF7 and Hela cell lines were carried out. It was thought that the knowledge achieved in this study would contribute to using 99mTc(CO)3-HU complex as an imaging agent, which inhibits the DNA synthesis selectively, by inhibiting ribonucleotide reductase enzyme. It was observed that FITC-HU has noteworthy incorporation on both cell lines. © Copyright 2016, Mary Ann Liebert, Inc. 2016.en_US
dc.identifier.doi10.1089/cbr.2015.1886en_US
dc.identifier.endpage19en_US
dc.identifier.issn1084-9785
dc.identifier.issue1en_US
dc.identifier.pmid26844848en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage14en_US
dc.identifier.urihttps://doi.org/10.1089/cbr.2015.1886
dc.identifier.urihttps://hdl.handle.net/11454/25763
dc.identifier.volume31en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherMary Ann Liebert Inc.en_US
dc.relation.ispartofCancer Biotherapy and Radiopharmaceuticalsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectantineoplasticen_US
dc.subjectfluorescence imagingen_US
dc.subjecthydroxyureaen_US
dc.subjectin vitro/in vivoen_US
dc.subject[99mTc(CO)3]+ coreen_US
dc.titleIn Vitro/In Vivo Evaluation of Radiolabeled [99mTc(CO)3]+-Hydroxyurea and Fluorescein Isothiocyanate-Hydroxyureaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu